Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

First-of-its-kind Doptelet will soon be Available to Control Life-threatening Bleeding

Dova Pharmaceuticals announced that US Food and Drug Administration (FDA) has given green signal to Doptelet (avatrombopag) prescriptive medicine for the treatment of thrombocytopenia in adult patients affecting with a chronic liver disease.

Doptelet is used to treat low platelet counts in adults affecting with severe liver disease and who are scheduled to undergo a treatment.

With the help of Doptelet, the CLD patients can minimise platelet transfusion prior to a procedure by increasing platelet counts to the target level of greater or equal to 50,000 per microliter and reduce the risk of bleeding.

A through trials of testing and reviewing was conducted by FDA in adults suffering with thrombocytopenia included Two global Phase 3, double-blind, placebo-controlled trials (ADAPT-1 [N=231] and ADAPT-2 [N=204]).

On a daily basis for 5 days the patients were allotted to consume 40 mg/60 mg of avatrombopag depending on their Baseline platelet counts (40 to <50>

Thrombocytopenia is a depletion of platelets in the blood of patients suffering from CLD.

Nearly 70,000 patients with CLD have a platelet count of less than 50,000/µL. Every year these patients require multiple invasive diagnostic and therapeutic procedures that lead to a high risk of bleeding.

Besides, Dova is also working on the evaluation of DOPTELET in the treatment of chemotherapy-induced thrombocytopenia (CIT).

The breakthrough medicine is scheduled to launch in the market in the month of June 2018.

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024BIOVIA from Molecule to MedicineCPHI China || PMEC China 2024Advance DoE WorkshopAsia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024